In the past decade, the landscape of drug development in oncology has evolved dramatically; however, this paradigm shift remains to be adopted in early phase clinical trial designs for studies of molecularly targeted agents and immunotherapeutic agents in paediatric malignancies. In drug development, prioritization of drugs on the basis of knowledge of tumour biology, molecular 'drivers' of disease and a drug's mechanism of action, and therapeutic unmet needs are key elements; these aspects are relevant to early phase paediatric trials, in which molecular profiling is strongly encouraged. Herein, we describe the strategy of the Innovative Therapies for Children with Cancer (ITCC) Consortium, which advocates for the adoption of trial designs that enable uninterrupted patient recruitment, the extrapolation from studies in adults when possible, and the inclusion of expansion cohorts. If a drug has neither serious dose-related toxicities nor a narrow therapeutic index, then studies should generally be started at the adult recommended phase II dose corrected for body surface area, and act as dose-confirmation studies. The use of adaptive trial designs will enable drugs with promising activity to progress rapidly to randomized studies and, therefore, will substantially accelerate drug development for children and adolescents with cancer.
Your institute does not have access to this article
Open Access articles citing this article.
Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group
Pediatric Research Open Access 07 June 2021
British Journal of Cancer Open Access 27 October 2020
Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia
Clinical Epigenetics Open Access 10 December 2019
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Pritchard-Jones, K. & Sullivan, R. Children with cancer: driving the global agenda. Lancet Oncol. 14, 189–191 (2013).
Skinner, R., Wallace, W. H. B., Levitt, G. A. & UK Children's Cancer Study Group (UKCCSG) Late Effects Group (LEG). Long-term follow-up of people who have survived cancer during childhood. Lancet Oncol. 7, 489–498 (2006).
Di Martino, S. et al. Overview of FDA-approved anti cancer drugs used for targeted therapy. World Cancer Res. J. 2, e553 (2015).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Smith, M. et al. Conduct of phase I trials in children with cancer. J. Clin. Oncol. 16, 966–978 (1998).
Zwaan, C. M. et al. The role of the 'innovative therapies for children with cancer' (ITCC) European consortium. Cancer Treat. Rev. 36, 328–334 (2010).
Pharmaceutical Research and Manufacturers of America. List of 2015 medicines in development for cancer 2015. PhRMA http://phrma-docs.phrma.org/sites/default/files/pdf/2014-cancer-report.pdf (2014).
Vassal, G., Geoerger, B. & Morland, B. Is the European pediatric medicine regulation working for children and adolescents with cancer? Clin. Cancer Res. 19, 1315–1325 (2013).
National Cancer Institute. Targeted cancer therapies. Cancer https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet (2017).
Postel-Vinay, S. et al. Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? Br. J. Cancer 100, 1373–1378 (2009).
Gupta, S. et al. Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. J. Natl Cancer Inst. 104,1860–1866 (2012).
Moreno García, V. et al. Dose-response relationship in phase I clinical trials: a European Drug Development Network (EDDN) Collaboration Study. Clin. Cancer Res. 20, 5663–5671 (2014).
Vassal, G. et al. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. Eur. J. Cancer 51, 218–224 (2015).
Vassal, G. et al. New drugs for children and adolescents with cancer: the need for novel development pathways. Lancet Oncol. 14, e117–e124 (2013).
Vassal, G. Will children with cancer benefit from the new European Paediatric Medicines Regulation? Eur. J. Cancer 45, 1535–1546 (2009).
Rocchi, F. et al. The European paediatric legislation: benefits and perspectives. Ital. J. Pediatr. 36, 56 (2010).
Vassal, G., Blanc, P. & Pearson, A. Need for change in implementation of paediatric regulation. Lancet Oncol. 14, 1156–1157 (2013).
Regulation (EC) No 1901/2006 of the European Parliament and of the council of 12 December 2006. http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf (2006).
Committee on Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA), Board on Health Sciences Policy & Institute of Medicine. Safe and Effective Medicines for Children: Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act (eds Field, M. J. & Boat, T. F.) (National Academies Press, 2012).
Food and Drug Administration. Pediatric Research Equity Act of 2003. FDA http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM077853.pdf (2003).
Yu, A. L. et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363, 1324–1334 (2010).
Le Tourneau, C., Gan, H. K., Razak, A. R. & Paoletti, X. Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents. PLoS ONE 7, e51039 (2012).
Skolnik, J. M., Barrett, J. S., Jayaraman, B., Patel, D. & Adamson, P. C. Shortening the timeline of pediatric phase I trials: the rolling six design. J. Clin. Oncol. 26, 190–195 (2008).
Paoletti, X. et al. A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trials. Eur. J. Cancer 49, 2392–2402 (2013).
Pearson, A. D. et al. Implementation of mechanism of action biology-driven early drug development for children with cancer. Eur. J. Cancer 62, 124–131 (2016).
Le Tourneau, C., Diera, V., Tresca, P., Cacheux, W. & Paoletti, X. Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents. Target. Oncol. 5, 65–72 (2010).
Lee, D. P. et al. Pediatric phase I trials in oncology: an analysis of study conduct efficiency. J. Clin. Oncol. 23, 8431–8441 (2005).
DuBois, S. G. et al. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a Children's Oncology Group study. Clin. Cancer Res. 17, 5113–5122 (2011).
Chu, T. F. et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370, 2011–2019 (2007).
World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310, 2191–2194 (2013).
Norris, R. E. & Adamson, P. C. Challenges and opportunities in childhood cancer drug development. Nat. Rev. Cancer 12, 776–782 (2012).
Carceller, F. et al. Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: an Innovative Therapies for Children with Cancer (ITCC) study. Eur. J. Cancer 67, 130–140 (2016).
Zwaan, C. M. et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. J. Clin. Oncol. 31, 2460–2468 (2013).
European Medicines Agency. Reflection paper on extrapolation of efficacy and safety in paediatric medicine development. EMA http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/04/WC500204187.pdf (2016).
Locatelli, F. et al. Phase 1/2 study in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia receiving blinatumomab treatment. Blood 124, 2292 (2014).
Wayne, A. S. et al. Pediatric phase 1 trial of moxetumomab pasudotox: activity in chemotherapy refractory acute lymphoblastic leukemia (ALL) [abstract]. Cancer Res. 74 (19 Suppl.), CT230 (2014).
Geoerger, B. et al. Innovative therapies for children with cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol. 13, 109–118 (2011).
Muller, P. Y. & Milton, M. N. The determination and interpretation of the therapeutic index in drug development. Nat. Rev. Drug Discov. 11, 751–761 (2012).
Kieran, M. W. et al. Phase 1 study of dabrafenib in pediatric patients with relapsed or refractory BRAF V600E high- and low-grade gliomas, Langerhans cell histiocytosis, and other solid tumors [abstract]. J. Clin. Oncol. 33 (Suppl.), 10004 (2015).
Bland, M. Detecting a single event. University of York https://www-users.york.ac.uk/∼mb55/bsi_study/single_event.pdf (2013).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01077544 (2015).
Neville, K. et al. Phase I/II study of brentuximab vedotin in pediatric patients with relapsed or refractory Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: interim phase I safety data [abstract]. J. Clin. Oncol. 31 (Suppl.), 10028 (2013).
Locatelli, F. et al. Phase 1/2 study of brentuximab vedotin in pediatric patients with relapsed or refractory Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: preliminary phase 2 data for brentuximab vedotin 1.8 mg/kg in the Hodgkin lymphoma study arm. Blood 122, 4378 (2013).
Olmos, D. et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751, 871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol. 11, 129–135 (2010).
Juergens, H. et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J. Clin. Oncol. 29, 4534–4540 (2011).
Malempati, S. et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J. Clin. Oncol. 30, 256–262 (2012).
Pappo, A. S. et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J. Clin. Oncol. 29, 4541–4547 (2011).
Frappaz, D. et al. Phase I study of dalotuzumab monotherapy and combination therapy ridaforolimus-dalotuzumab in pediatric patients with advanced solid tumors. Eur. J. Cancer 62, 9–17 (2016).
Neuenschwander, B., Branson, M. & Gsponer, T. Critical aspects of the Bayesian approach to phase I cancer trials. Stat. Med. 15, 2420–2439 (2008).
O'Quigley, J., Pepe, M. & Fisher, L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 46, 33–48 (1990).
Onar-Thomas, A. & Xiong, Z. A simulation-based comparison of the traditional method, rolling-6 design and a frequentist version of the continual reassessment method with special attention to trial duration in pediatric phase I oncology trials. Contemp. Clin. Trials 31, 259–270 (2010).
Zhao, L., Lee, J., Mody, R. & Braun, T. M. The superiority of the time-to-event continual reassessment method to the rolling six design in pediatric oncology phase I trials. Clin. Trials 8, 361–369 (2011).
Doussau, A. et al. Dose-finding designs in pediatric phase I clinical trials: comparison by simulations in a realistic timeline framework. Control. Clin. Trials 33, 657–665 (2012).
Doussau, A., Geoerger, B., Jiménez, I. & Paoletti, X. Innovations for phase I dose-finding designs in pediatric oncology clinical trials. Contemp. Clin. Trials. 47, 217–227 (2016).
Simon, R. et al. Accelerated titration designs for phase I clinical trials in oncology. J. Natl Cancer Inst. 89, 1138–1147 (1997).
Manji, A. et al. Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. J. Clin. Oncol. 31, 4260–4267 (2013).
Ensign, L. G., Gehan, E. A., Kamen, D. S. & Thall, P. F. An optimal three-stage design for phase II clinical trials. Stat. Med. 13, 1727 (1994).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02813135 (2016).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02432274 (2017).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02124772 (2017).
Moroz, V., Wilson, J. S., Kearns, P. & Wheatley, K. Comparison of anticipated and actual control group outcomes in randomised trials in paediatric oncology provides evidence that historically controlled studies are biased in favour of the novel treatment. Trials 15, 481 (2014).
Saad, E. D., Paoletti, X., Burzykowski, T. & Buyse, M. Precision medicine needs randomized clinical trials. Nat. Rev. Clin. Oncol. http://dx.doi.org/10.1038/nrclinonc.2017.8 (2017).
Billingham, L., Malottki, K. & Steven, N. Research methods to change clinical practice for patients with rare cancers. Lancet Oncol. 17, e70–e80 (2016).
Jung, S. H. Randomized phase II trials with a prospective control. Stat. Med. 27, 568–583 (2008).
Jakacki, R. et al. Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study. J. Neurooncol. 129, 131–138 (2016).
Mody, R. et al. Phase II randomized trial of irinotecan/temozolomide (I/T) with temsirolimus (TEM) or dinutuximab plus granulocyte colony stimulating factor (DIN/GMCSF) in children with refractory or relapsed neuroblastoma: a report from the Children's Oncology Group (COG) [abstract]. J. Clin. Oncol. 34 (Suppl.), 10502 (2016).
Moreno, L. et al. A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma — BEACON-Neuroblastoma, a European Innovative Therapies for Children with Cancer (ITCC) — International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial [abstract]. J. Clin. Oncol. 33 (Suppl.), TPS10082 (2015).
Corbacioglu, S. et al. The RIST design: a molecularly targeted multimodal approach for the treatment of patients with relapsed and refractory neuroblastoma [abstract]. J. Clin. Oncol. 31 (Suppl.), 10017 (2013).
Kager, L. et al. The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24–25, 2015. Workshop Report. Clin. Sarcoma Res. 6, 3 (2016).
Malempati, S. et al. Early results from Children's Oncology Group (COG) ARST08P1: pilot studies of cixutumumab or temozolomide with intensive multiagent chemotherapy for patients with metastatic rhabdomyosarcoma [abstract]. J. Clin. Oncol. 33 (Suppl.), 10015 (2015).
Yap, T. A., Sandhu, S. K., Workman, P. & de Bono, J. S. Envisioning the future of early anticancer drug development. Nat. Rev. Cancer 10, 514–523 (2010).
Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89–95 (2001).
Fouladi, M. et al. A phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study. Pediatr. Blood Cancer 61, 1246–1251 (2014).
Moreno, L. et al. Phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin. Cancer Res. 21, 267–273 (2015).
Smith, J. R. et al. Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma. Mol. Oncol. 10, 538–552 (2016).
Siravegna, G., Marsoni, S., Siena, S. & Bardelli, A. Integrating liquid biopsies intro the management of cancer. Nat. Rev. Clin. Oncol. http://dx.doi.org/10.1038/nrclinonc.2017.14 (2017).
Glade Bender, J. L. et al. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a Children's Oncology Group Phase I Consortium report. J. Clin. Oncol. 31, 3034–3043 (2013).
Sedlacik, J. et al. MR imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine glioma. AJNR Am. J. Neuroradiol. 34, 1450–1455 (2013).
Schleiermacher, G. et al. Emergence of new ALK mutations at relapse of neuroblastoma. J. Clin. Oncol. 32, 2727–2734 (2014).
Hill, R. M. et al. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer Cell 27, 72–84 (2015).
Carr-Wilkinson, J. et al. High frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed neuroblastoma. Clin. Cancer Res. 16, 1108–1118 (2010).
Chicard, M. et al. Genomic copy number profiling using circulating free tumor DNA highlights heterogeneity in neuroblastoma. Clin. Cancer Res. 22, 5564–5573 (2016).
Combaret, V. et al. Detection of tumor ALK status in neuroblastoma patients using peripheral blood. Cancer Med. 4, 540–550 (2015).
Geoerger, B. et al. Molecular screening for cancer treatment optimization (MOSCATO 01) in pediatric patients: first feasibility results of a prospective molecular stratification trial [abstract]. J. Clin. Oncol. 32 (Suppl.), 10500 (2014).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02613962 (2017).
Worst, B. C. et al. Next-generation personalised medicine for high-risk paediatric cancer patients — the INFORM pilot study. Eur. J. Cancer 65, 91–101 (2016).
Netherlands Trial Register. Towards individualized therapy for patients with pediatric tumors. http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=5915 (2016).
National Cancer Institute. NCI-MATCH trial (molecular analysis for therapy choice). Cancer https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match (2017).
Harris, M. H. et al. Multicenter feasibility study of tumor molecular profiling to inform therapeutic decisions in advanced pediatric solid tumors: the Individualized Cancer Therapy (iCat) study. JAMA Oncol. 2, 608–615 (2016).
Kearns, G. L. et al. Developmental pharmacology — drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349, 1157–1167 (2003).
Veal, G. J. et al. Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens. Cancer Chemother. Pharmacol. 77, 685–692 (2016).
Food and Drug Administration, HHS. International Conference on Harmonisation; guidance on E11 clinical investigation of medicinal products in the pediatric population; availability. Notice. Fed. Regist. 65, 78493–78494 (2000).
Momper, J. D. et al. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007. JAMA Pediatr. 167, 926–932 (2013).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01353625 (2016).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02304458 (2017).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01524926 (2016).
Voss, S. D. et al. Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium. Pediatr. Blood Cancer 62, 45–51 (2015).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01390948 (2016).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01956669 (2017).
Kimura, H., Ng, J. M. & Curran, T. Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell 13, 249–260 (2008).
Geoerger, B. et al. A phase I/II study of LDE225, a smoothened antagonist, in pediatric patients with recurrent medulloblastoma or other solid tumors [abstract]. J. Clin. Oncol. 30 (Suppl.), 9519 (2012).
Gajjar, A. et al. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a Pediatric Brain Tumor Consortium study. Clin. Cancer Res. 19, 6305–6312 (2013).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01125800 (2017).
Goteke, V. K. R. et al. An anthropometric study in children with chronic myeloid leukemia on imatinib [abstract]. J. Clin. Oncol. 30 (Suppl.), 6554 (2012).
Shima, H. et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J. Pediatr. 159, 676–681 (2011).
PanCare. Pan-European network for care of survivors after childhood and adolescent cancer. PanCare http://www.pancare.eu (2017).
Dupont, J. C., Pritchard-Jones, K. & Doz, F. Ethical issues of clinical trials in paediatric oncology from 2003 to 2013: a systematic review. Lancet Oncol. 17, e187–e197 (2016).
Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A. Jr & Kinzler, K.W. Cancer genome landscapes. Science 339, 1546–1558 (2013).
Trippett, T. M. et al. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the Pediatric Oncology Experimental Therapeutic Investigators' Consortium. J. Clin. Oncol. 27, 5102–5108 (2009).
Glade Bender, J. L. et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group study. J. Clin. Oncol. 26, 399–405 (2008).
Daw, N. C. et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group study. J. Clin. Oncol. 23, 6172–6180 (2005).
L.M. has received funding support from the Oak Foundation. The work of A.D.J.P. has been funded through a Cancer Research UK Life Chair and Programme Grant included within a Cancer Research UK ICR Core Award (C347/A15403), and is supported by the NIHR RM/ICR Biomedical Research Centre. C.M.Z. receives support from a KiKa-foundation (project 113) grant. We thank M. White (freelance editor and medical writer) for editorial support in the preparation of this article and G. Cook for administrative assistance. Editorial support costs have been funded by institutional funds from CNIO–HNJ Clinical Research Unit at Hospital Niño Jesus
The authors declare no competing financial interests.
About this article
Cite this article
Moreno, L., Pearson, A., Paoletti, X. et al. Early phase clinical trials of anticancer agents in children and adolescents — an ITCC perspective. Nat Rev Clin Oncol 14, 497–507 (2017). https://doi.org/10.1038/nrclinonc.2017.59
Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group
Pediatric Research (2022)
British Journal of Cancer (2021)
Cancer and Metastasis Reviews (2020)
A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Clinical Pharmacokinetics (2020)
Nature Reviews Cancer (2019)